ELEV vs. FENC, KOD, ADVM, IPSC, GNFT, INMB, CGEN, OPT, IPHA, and CLLS
Should you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Fennec Pharmaceuticals (FENC), Kodiak Sciences (KOD), Adverum Biotechnologies (ADVM), Century Therapeutics (IPSC), Genfit (GNFT), INmune Bio (INMB), Compugen (CGEN), Opthea (OPT), Innate Pharma (IPHA), and Cellectis (CLLS). These companies are all part of the "biological products, except diagnostic" industry.
Elevation Oncology (NASDAQ:ELEV) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, community ranking, media sentiment, institutional ownership, dividends, valuation and risk.
Fennec Pharmaceuticals has higher revenue and earnings than Elevation Oncology. Fennec Pharmaceuticals is trading at a lower price-to-earnings ratio than Elevation Oncology, indicating that it is currently the more affordable of the two stocks.
Elevation Oncology has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Fennec Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.
Elevation Oncology presently has a consensus price target of $7.40, suggesting a potential upside of 101.09%. Fennec Pharmaceuticals has a consensus price target of $16.00, suggesting a potential upside of 135.64%. Given Fennec Pharmaceuticals' higher possible upside, analysts clearly believe Fennec Pharmaceuticals is more favorable than Elevation Oncology.
In the previous week, Fennec Pharmaceuticals had 13 more articles in the media than Elevation Oncology. MarketBeat recorded 19 mentions for Fennec Pharmaceuticals and 6 mentions for Elevation Oncology. Elevation Oncology's average media sentiment score of 0.63 beat Fennec Pharmaceuticals' score of 0.04 indicating that Elevation Oncology is being referred to more favorably in the media.
83.7% of Elevation Oncology shares are owned by institutional investors. Comparatively, 55.5% of Fennec Pharmaceuticals shares are owned by institutional investors. 14.9% of Elevation Oncology shares are owned by insiders. Comparatively, 11.3% of Fennec Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Elevation Oncology has a net margin of 0.00% compared to Fennec Pharmaceuticals' net margin of -75.50%. Fennec Pharmaceuticals' return on equity of 0.00% beat Elevation Oncology's return on equity.
Fennec Pharmaceuticals received 168 more outperform votes than Elevation Oncology when rated by MarketBeat users. However, 69.44% of users gave Elevation Oncology an outperform vote while only 65.65% of users gave Fennec Pharmaceuticals an outperform vote.
Summary
Elevation Oncology beats Fennec Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Elevation Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELEV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elevation Oncology Competitors List
Related Companies and Tools
